22
Participants
Start Date
October 31, 2010
Primary Completion Date
September 30, 2017
Study Completion Date
September 30, 2017
bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
Memorial Sloan-Kettering Cancer Center, New York
Collaborators (1)
Genentech, Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER